Evidence map›Paper›PMID 39902862›Full record

ArticleOncoimmunology2025

Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site.

Maria Paula Roberti, Pornpimol Charoentong, Yanhong Lyu, Marten Meyer, Stefan B Eichmüller, Patrick Schmidt, Frank Momburg, Miray Cetin, Felix Hartmann, Nektarios A Valous and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Cancer vaccines: advances, hurdles, and future directions.Exploration of targeted anti-tumor therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maria Paula RobertiClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-5788-6840
Pornpimol CharoentongClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yanhong LyuMedical Faculty Heidelberg, Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Marten MeyerClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan B EichmüllerGMP and T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Patrick SchmidtMedical Faculty Heidelberg, Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Frank MomburgClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Miray CetinSystems Immunology and Single Cell Biology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felix HartmannSystems Immunology and Single Cell Biology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nektarios A ValousClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Laura MichelMedical Faculty Heidelberg, Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Peter LichterNational Center for Tumor Diseases (NCT) Heidelberg, A partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany.
Andreas SchneeweissDivision of Gynecological Oncology, National Center for Tumor Diseases (NCT), A partnership between DKFZ and Heidelberg University Medical Center, Heidelberg University Hospital, Heidelberg, Germany.
Verena ThewesNational Center for Tumor Diseases (NCT) Heidelberg, A partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany.
Carlo FremdMedical Faculty Heidelberg, Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Inka ZörnigClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dirk JägerClinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells that recognize tumor-specific mutations are crucial for cancer immunosurveillance and in adoptive transfer of TILs or transgenic-TCR T cell products. However, their challenging identification and isolation limits their use in clinical practice. Therefore, novel approaches to isolate tumor-specific T cells are needed. Here, we report the isolation of neoantigen-specific CD8

Indexed as

Antigens, NeoplasmBreast NeoplasmsCancer VaccinesCD8-Positive T-LymphocytesReceptors, Antigen, T-CellSkinBiopsyFemaleHumansLymphocytes, Tumor-InfiltratingMutationVaccinationAntigens, NeoplasmCancer VaccinesReceptors, Antigen, T-Celladoptive T cell therapyBreast cancerneoantigenpeptide vaccineT cell receptor engineered T cellsTILsvaccination site infiltrating lymphocytesVILs

Identifiers

PMID39902862
PMCPMC11796541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.